Advicenne S.A.

Paris Stock Exchange ALDVI.PA

Advicenne S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 4.67 M

Advicenne S.A. Net Cash Used Provided By Financing Activities is USD 4.67 M for the year ending December 31, 2023, a -8.70% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Advicenne S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 5.12 M, a -49.54% change year over year.
  • Advicenne S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 10.14 M, a -33.74% change year over year.
  • Advicenne S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 15.31 M, a 1,287.39% change year over year.
  • Advicenne S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 1.10 M, a 68.81% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
Paris Stock Exchange: ALDVI.PA

Advicenne S.A.

CEO Mr. Didier Laurens
IPO Date Dec. 6, 2017
Location France
Headquarters 3ème étage 262
Employees 21
Sector Healthcare
Industries
Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Eyewear Fertilizers Glass
Description

Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.

StockViz Staff

February 6, 2025

Any question? Send us an email